Retrovirally transduced human dendritic cells can generate T cells recognizing multiple MHC class I and class II epitopes from the melanoma antigen glycoprotein 100

Journal of Immunology

Volumn 167, Issue 8, 2001, Pages 4758-4764

  Lapointe, R ^a   Royal, R E ^a   Reeves, M E ^a   Altomare, I ^a   Robbins, P F ^a   Hwu, P ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; EPITOPE; GLYCOPROTEIN; HLA A2 ANTIGEN; HLA DR ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MELANOMA ANTIGEN;

ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DENDRITIC CELL; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MELANOMA; MIXED LYMPHOCYTE REACTION; PRIORITY JOURNAL; RETROVIRUS; T LYMPHOCYTE;

EID: 0035887664     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.167.8.4758     Document Type: Article

References (42)

1. A new era for cancer immunotherapy based on the genes that encode cancer antigens
2. Cancer-testis antigens: Targets for cancer immunotherapy
3. Tumor antigens recognized by T cells
4. Cancer vaccines: Cancer antigens; differentiation antigens
5. Cancer vaccines: Cancer antigens; oncogenes and mutations
6. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
7. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens
8. Dendritic cells and the control of immunity
9. Immunobiology of dendritic cells
10. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells
11. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo
12. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs
13. Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells
14. Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses
15. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses
16. Dendritic cells in cancer immunotherapy
17. Dendritic cell based tumor vaccines
18. Phosphorylated peptides are naturally processed and presented by major histocompatibility complex class I molecules in vivo
19. An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins
20. A comparison of gene transfer methods in human dendritic cells
21. Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine
22. Retroviral transduction of human dendritic cells with a tumor-associated antigen gene
23. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases
24. + T cell reactivity to a model tumor antigen
25. + T cells in the antitumor immune response
26. + T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene
27. Generation of gene-modified T cells reactive against the angiogenic kinase insert domain-containing receptor (KDR) found on tumor vasculature
28. The pCL vector system: Rapid production of helper-free, high-titer, recombinant retroviruses
29. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides
30. Human dendritic cells require multiple activation signals for the efficient generation of tumor antigen-specific T lymphocytes
31. Anti-tumor immunization with a minimal peptide epitope (G9-209-2M) leads to a functionally heterogeneous CTL response
32. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression
33. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues
34. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles
35. Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice
36. + T cell epitopes from NY-ESO-1 presented by HLA-DR molecules
37. Intracellular sorting and targeting of melanosomal membrane proteins: Identification of signals for sorting of the human brown locus protein, gp75
38. + T cell responses
39. + T cell deletion induced by cross-presentation of self-antigens and favors autoimmunity
40. + cytotoxic T-cell responses during chronic viral infection
41. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses
42. + T-helper and a T-killer cell